Additional file 1 of Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer

Additional file 1: Supplementary Fig. 1. The expression of WDR5 in age, gender, T-stage, N-stage and Non-muscle invasive bladder cancer (NMIBC) history features in TCGA cohort. Supplementary Fig. 2. The images of EdU assay of three BCa cells treated with two doses of OICR-9429 or DMSO. Supplementary Fig. 3. OICR-9429 increases apoptosis of bladder cancer cells. Supplementary Fig. 4. OICR-9429 increases cisplatin chemosensitivity of bladder cancer cells but not gemcitabine. Supplementary Fig. 5. H&E staining of kidney, liver, lung, and heart from the mice in indicated groups. Supplementary Fig. 6. The target genes of OICR-9429 are identified in bladder cancer. Supplementary Fig. 7. Pearson correlations between the expression of WDR5 and CDK1, PLK1, CCNE2, CCNB1, BIRC5, XRCC2, MCM2, AURKA and FOXM1 in TCGA cohort. Supplementary Fig. 8. OICR-9429 treatment did not affect H3K4me3 and RNA polymerase-II levels on the promoter regions of CDK1 and MCM2 in UM-UC-3 and T24 cells. Supplementary Fig. 9. Original images of western blotting. Supplementary Table 1. Univariate and multivariate analysis of factors associated with overall survival in 345 cases of bladder cancer from TCGA cohort. Supplementary Table 2. Primers used in qPCR. Supplementary Table 3. Primers used in ChIP-qPCR.